Find disease awareness content and relevant supporting materials

The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and...

The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination (FAD) recommending Blincyto (blinatumomab) from...

The European Commission has granted conditional marketing authorization for Blincyto (blinatumomab), from Amgen, for the treatment of adults with Philadelphia...

To evaluate the rate of complete remission/complete remission with partial hematological recovery (CR/CRh*) in adult subjects with Relapsed/Refractory (R/R) Philadelphia...

Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for Blincyto (blinatumomab) to include...

Kite, a Gilead Company announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/II study evaluating its chimeric antigen receptor (CAR) T-cell therapy Tecartus (brexucabtagene autoleucel)(KTE 19) in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric...

Amgen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include overall survival...

Amgen has announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival...

This study seeks adult subjects with R/R Ph+ B-precursor ALL. This is a single-arm Simon II stage design, multicenter study...